国家中药Ⅱ类新药生血宁片治疗缺铁性贫血疗效显著,成人临床治愈率达90%。据悉,这是我国第一个具有自主知识产权的治缺铁性贫血新药。该成果最近获浙江省中医药科技创新一等奖。 我国缺铁性贫血发病率较高,达15%～30%,育龄期妇女达40%～50%,婴幼儿和中小学生发病率高达64.4 The Chinese medicine II type new drug Shengxuening Tablets is effective in treating iron deficiency anemia, and the clinical cure rate for adults is 90%. It is reported that this is China’s first new drug to treat iron deficiency anemia with independent intellectual property rights. This achievement was recently awarded the first prize for Zhejiang Provincial Technological Innovation in Traditional Chinese Medicine. The incidence of iron-deficiency anaemia is high in China, reaching 15% to 30%, 40% to 50% for women of childbearing age, and the incidence rate for infants, children, and elementary and middle school students is as high as 64.4.